Reply

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 3, 2013, Pages 328-

  Sin, Don D ^a,b   Van Eeden, Stephan ^a,b   Leipsic, Jonathon ^a,b   Man, S F Paul ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CIGARETTE SMOKE; LOSARTAN; TRANSFORMING GROWTH FACTOR BETA;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; LUNG EMPHYSEMA; MARFAN SYNDROME; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; CARDIOVASCULAR DISEASE; INFLAMMATION; LUNG DISEASE; NOTE;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; LUNG DISEASES;

EID: 84873351668     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201206-1023IM     Document Type: Letter

References (2)

1. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312:117-121.
2. Churg A, Sin DD, Wright JL. Everything prevents emphysema: are animal models of cigarette smoke-induced chronic obstructive pulmonary disease any use? Am J Respir Cell Mol Biol 2011;45:1111-1115.